The primary objectives of this study are to determine the efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks as measured by the proportion of participants with sustained viral response 12 weeks after cessation of treatment (SVR12) and to evaluate the safety and tolerability of treatment with SOF/VEL/VOX FDC.